Prilenia to present latest research from its pridopidine programs for huntington disease and als at aan 2024

Naarden, netherlands & waltham, mass.--(business wire)--prilenia therapeutics b.v., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the presentation of the latest research from the pridopidine huntington disease (hd) and amyotrophic lateral sclerosis (als) programs at the american academy of neurology (aan) annual congress, in denver, colorad.
MT Ratings Summary
MT Quant Ranking